

Neola Medical Granted Patent in the USA

Neola Medical AB has been granted a patent in the USA that strengthens the protection of the company's innovation pipeline of medical device for continuous lung monitoring. The granted patent is for a technical method which opens opportunities for lung monitoring of more patient groups than preterm born infants, and part of a patent family related to positioning the light source inside the body when measuring gas in the lungs. The approved patent is crucial for future measurements on larger patients, such as children and adults. The patent is pending in Europe and in China.

"The approval of this patent not only solidifies our competitive position in the American market but also protects a critical aspect of our technology pipeline. This patent is a cornerstone in our strategy to innovate and deliver next-generation lung monitoring solutions for patients in intensive care, including both children and adults.", says CEO Hanna Sjöström.

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Attachments

[Neola Medical Granted Patent in the USA](#)